The Development of Pancreatic Injury in the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Pancreatic Injury in Patients With COVID-19 Disease
1 other identifier
observational
500
1 country
1
Brief Summary
Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common. In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury in the course of COVID 19 disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 11, 2020
CompletedFirst Submitted
Initial submission to the registry
June 12, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 12, 2020
CompletedFirst Posted
Study publicly available on registry
June 16, 2020
CompletedJune 16, 2020
June 1, 2020
3 months
June 12, 2020
June 15, 2020
Conditions
Outcome Measures
Primary Outcomes (4)
to compare presence of fever in patients with and without pancreatic injury
To evaluate the frequency of presence of fever in patients with and without pancreatic injury
3 month
to compare presence of dyspnea in patients with and without pancreatic injury
To evaluate the frequency of presence of dyspnea in patients with and without pancreatic injury
3 month
To compare cRP levels in patients with and without pancreatic injury
CRP levels will be compared in patients with and without pancreatic injury
3 month
To compare d-dimer levels in patients with and without pancreatic injury
D-Dimer levels will be compared in patients with and without pancreatic injury
3 month
Study Arms (2)
patients with pancreatic injury
patients with higher amylase and lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection
patients without pancreatic injury
patients with normal amylase and lipase levels in the course of SARS-CoV-2 infection
Interventions
cRP, d-dimer levels and lymphocyte counts will be compared
Eligibility Criteria
Patients who develop amylase and lipase elevation during the course of COVID 19 will be considered in the pancreatic injury group. Those who do not develop will be counted as the control group.
You may qualify if:
- Patients with amylase and lipase levels measured during covid-19 disease with or without pneumonia
You may not qualify if:
- Patients with pregnancy
- Patients whose amylase and lipase levels were not measured during covid 19 disease
- Patients with known solid organ malignacy
- Patients with known hematologic malignacy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Uşak Universitylead
Study Sites (1)
Usak University Training and Research Hospital
Uşak, 64200, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, M.D.
Study Record Dates
First Submitted
June 12, 2020
First Posted
June 16, 2020
Study Start
March 1, 2020
Primary Completion
June 11, 2020
Study Completion
June 12, 2020
Last Updated
June 16, 2020
Record last verified: 2020-06
Data Sharing
- IPD Sharing
- Will not share